How has been the historical performance of Glaxosmi. Pharma?

Answer:The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profit over the years leading up to March 2025.

Breakdown:
Glaxosmi. Pharma's net sales have increased from 3,128.12 Cr in March 2019 to 3,749.21 Cr in March 2025, reflecting a steady growth trajectory. The total operating income followed a similar pattern, rising from 3,128.12 Cr in March 2019 to 3,749.21 Cr in March 2025. The operating profit (PBDIT) also saw significant growth, climbing from 703.11 Cr in March 2019 to 1,323.29 Cr in March 2025, indicating improved operational efficiency with an operating profit margin that increased from 19.21% to 31.4% over the same period. Profit before tax rose from 682.66 Cr in March 2019 to 1,259.88 Cr in March 2025, while profit after tax surged from 445.39 Cr to 927.58 Cr, demonstrating a robust increase in profitability. The company's total assets increased from 3,025.05 Cr in March 2020 to 3,967.20 Cr in March 2025, with total liabilities also rising from 3,025.05 Cr to 3,967.20 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 1,289.00 Cr in March 2025 compared to 490.00 Cr in March 2020, while the closing cash and cash equivalents rose to 538.00 Cr in March 2025 from 104.00 Cr in March 2020, showcasing enhanced liquidity. Overall, Glaxosmi. Pharma has demonstrated strong financial performance with increasing sales, profits, and cash flow over the years.